Cardiovascular Disease, Mortality Risk, and Healthcare Costs by Lipoprotein(a) Levels According to Low‐density Lipoprotein Cholesterol Levels in Older High‐risk Adults

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cardiology

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/clc.22546PMID 27177347PMCID PMC5845436
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials

  2016cited by this paper
• Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention.

  2015cited by this paper
• Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients.

  2015cited by this paper
• Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

  2015cited by this paper
• Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.

  2015cited by this paper
• Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

  2015cited by this paper
• Lipoprotein(a) for risk assessment in patients with established coronary artery disease.

  2014cited by this paper
• Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study.

  2014cited by this paper
• Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study

  2013cited by this paper
• Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin)

  2013cited by this paper
• Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

  2013cited by this paper
• Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009-2010).

  2013cited by this paper
• Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

  2012cited by this paper
• Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterole

  2012cited by this paper
• Lipid-related markers and cardiovascular disease prediction.

  2012cited by this paper
• Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes.

  2012cited by this paper
• Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.

  2011cited by this paper
• Lipoprotein(a) as a cardiovascular risk factor: current status

  2010cited by this paper
• Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

  2009cited by this paper
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National

  2009cited by this paper
• General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study

  2008cited by this paper
• Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.

  2006cited by this paper
• Lp(a) lipoprotein, vascular disease, and mortality in the elderly☆

  2004cited by this paper
• Preventive cardiology: abstractLp (a) lipoprotein, vascular disease and mortality in the elderly

  2004cited by this paper
• Lp(a) lipoprotein, vascular disease, and mortality in the elderly.

  2003cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment.

  2002cited by this paper
• Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study

  1997cited by this paper
• Laboratory methods and quality assurance in the Cardiovascular Health Study.

  1995cited by this paper
• The Cardiovascular Health Study: design and rationale.

  1991cited by this paper
• A monoclonal-antibody-based enzyme-linked immunosorbent assay of lipoprotein(a).

  1990cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• The variations in health cost based on the traditional obesity parameters among patients with coronary artery diseases undergoing cardiac catheterization

  2024cites this paper
• Frequency & factors associated with elevated lipoprotein-a among Ghanaian stroke survivors.

  2023cites this paper
• Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis

  2023cites this paper
• Preparation, structural characterization and bioactivities of polysaccharides from mulberry (Mori Fructus)

  2022cites this paper
• Association of low-density lipoprotein cholesterol levels with the risk of mortality and cardiovascular events: A meta-analysis of cohort studies with 1,232,694 participants

  2022cites this paper
• Effect of Lipoprotein(a) on Stroke Recurrence Attenuates at Low LDL-C (Low-Density Lipoprotein) and Inflammation Levels

  2022cites this paper
• Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy

  2021cites this paper
• Lipoprotein (a) is associated with poor long-term prognosis in patients aged 80 years and older with acute coronary syndrome.

  2021cites this paper
• What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?

  2020cites this paper
• Linking electronic health data in pharmacoepidemiology: Appropriateness and feasibility

  2020cites this paper
• Lipoprotein(a) and cardiovascular death in oldest-old (≥80 years) patients with acute myocardial infarction: A prospective cohort study.

  2020cites this paper
• Elevated lipoprotein(a) and risk of coronary heart disease according to different lipid profiles in the general Chinese community population: the CHCN-BTH study

  2020cites this paper
• Lipoprotein (a) is a residual risk of atherosclerotic renal artery stenosis in hypertensive patients: a hospital-based cross-sectional study

  2020cites this paper
• Lipoprotein (a) is a residual risk of atherosclerotic renal artery stenosis in hypertensive patients: a population-based cross-sectional study.

  2020cites this paper
• High lipoprotein(a) and high risk of mortality.

  2019cites this paper
• Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives

  2019cites this paper
• Effects of Eicosapentaenoic Acid (EPA) on Mouse Endothelial Cell Health

  2018cites this paper
• Plasma Lipoprotein(a) Concentration Is Associated With the Coronary Severity but Not With Events in Stable Coronary Artery Disease Patients: A Chinese Cohort Study.

  2018cites this paper
• New diet trials and cardiovascular risk

  2018cites this paper
• Analysis of lipid metabolism and its impact on the risk of ischemic heart disease in patients with definite familial hypercholesterolemia.

  2017cites this paper
• Association of lipoprotein(a) with long‐term mortality following coronary angiography or percutaneous coronary intervention

  2017cites this paper
• LDL-cholesterol Predicts a First CHD Event in Senior Citizens, Especially So in Those With Elevated Lipoprotein(a): Dubbo Study of the Elderly.

  2017cites this paper
• Lipoprotein (a) Management: Lifestyle and Hormones.

  2017cites this paper
• Gut Microbiota: A New Marker of Cardiovascular Disease.

  2017cites this paper
• Management of Dyslipidemia in the Elderly

  2014cites this paper